PCNL (Percutaneous Nephrolithotomy) — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Percutaneous nephrolithotomy (PCNL) is a minimally invasive urological procedure to remove kidney stones too large, hard, or complex for extracorporeal shock wave lithotripsy (ESWL) or ureteroscopy. A nephroscope (rigid or flexible endoscope) is passed through a 1–2 cm incision in the skin of the flank directly into the kidney under X-ray and/or ultrasound guidance. Stones are fragmented using laser energy (holmium:YAG laser, 'dusting' or 'popcorn' technique), ultrasonic energy (ultrasonic lithotriptor), pneumatic energy (ballistic lithotriptor), or a combination (EMS SonoTrode dual-energy probe). The fragments are removed through the nephroscopic sheath. PCNL achieves stone-free rates of 85–95% for stones larger than 2 cm in a single procedure — superior to ESWL (60–70%) or ureteroscopy for stones of this size. The standard access size uses a 24–30 French (8–10 mm) nephroscopic sheath (standard PCNL). Mini-PCNL uses a 14–20 French sheath; ultra-mini PCNL uses an 11–13 French sheath; micro-PCNL uses a 4.8 French sheath. Smaller access sizes reduce bleeding and post-operative pain at the cost of longer operating times. The choice of access size is determined by stone burden, anatomy, and surgeon expertise. PCNL is particularly advantageous over ureteroscopy for stones in the lower calyx where access and fragmentation efficiency are lower. Miniaturised variants — mini-PCNL (20F), ultra-mini PCNL (11–13F), and micro-PCNL (4.85F) — use smaller nephrostomy tracts to reduce bleeding risk and recovery time for smaller stones. Tubeless PCNL (no nephrostomy tube post-procedure) and totally tubeless PCNL (no internal stent or nephrostomy) are feasible in selected cases with low complication risk, enabling same-day discharge.

PCNL is the preferred treatment for: large renal stones (>2 cm in any calyx, or >1.5 cm in the lower pole calyx where ESWL has poor stone-free rates due to gravity-impaired fragment clearance); staghorn calculi (stones that fill the renal pelvis and multiple calices — typically requiring multiple PCNL access tracts); stones refractory to ESWL after two to three sessions; stones in horseshoe, malrotated, or transplant kidneys with abnormal anatomy preventing ESWL targeting; cystine or brushite stones that are resistant to acoustic lithotripsy; and anatomical variants (ureteropelvic junction obstruction, calyceal diverticulum stones) that may be simultaneously addressed during PCNL. PCNL is contraindicated in untreated urinary tract infection (risk of urosepsis from opening the collecting system with active bacteriuria — urine must be sterile pre-operatively, confirmed by MSU culture), uncorrected coagulopathy or active anticoagulation, and pregnancy. Anticoagulation (warfarin, DOACs) must be stopped and bridging therapy planned with the anticoagulation team given the risk of significant renal haemorrhage. Pre-operative CT urogram defines stone size, composition density (Hounsfield units predict fragmentation resistance), calyceal anatomy, relationship to adjacent organs, and planned access route.

Under general or spinal anaesthesia, the patient is initially placed supine for cystoscopic retrograde insertion of a ureteric catheter (to opacify the collecting system with contrast for fluoroscopic guidance of the renal puncture). The patient is then turned prone (face down) or to a modified supine position (Valdivia/Galdakao position). The kidney's collecting system is identified on fluoroscopy and/or ultrasound. Using a Chiba needle, the target calyx (providing the best angle to access the stone) is punctured under fluoroscopic or ultrasound guidance through the skin and retroperitoneal fat, aiming for the papilla to enter the calyx at the fornix. Correct intrarenal position is confirmed by aspiration of urine and injection of contrast. A guidewire is advanced through the needle into the ureter. The tract is dilated sequentially using Amplatz dilators or a balloon dilator to the working sheath size (14–30 French). The nephroscope is inserted through the sheath. The stone is visualised and fragmented under direct vision using the chosen lithotripsy energy, then fragments are systematically removed by aspiration and forceps. After stone clearance, flexible nephroscopy inspects for residual fragments in all calices. A nephrostomy tube is placed through the access tract to allow drainage and is typically removed on day 1–2 (tubeless PCNL may forego the nephrostomy tube). A ureteric stent may be placed.

PCNL is the most effective single-session treatment for large and complex renal stones. Stone-free rates for stones 2–4 cm exceed 85–90% in experienced hands; for staghorn calculi (complete or partial), single-session clearance of 60–80% is achieved, with overall clearance exceeding 90% after staged sessions. These rates are substantially superior to ESWL (30–60% for stones >2 cm) and ureteroscopy (60–75% for stones >2 cm). Despite being an invasive procedure, PCNL's minimally invasive access through a small skin incision means recovery is dramatically faster than open kidney surgery — hospital stay 2–3 days versus 7–10 days, and return to work in 1–2 weeks. Modern miniaturised techniques (mini-PCNL, 14–20 French) further reduce blood loss, transfusion rates, and post-operative pain with equivalent stone clearance for stones under 2.5 cm, making PCNL appropriate for a wider range of patients including those with smaller or fewer stones who might previously have been managed with ureteroscopy. PCNL can simultaneously correct anatomical abnormalities such as ureteropelvic junction obstruction causing recurrent stone disease (endopyelotomy).

PCNL carries specific risks inherent to percutaneous renal access. Haemorrhage is the most significant complication: clinically significant bleeding requiring transfusion occurs in 5–7% of standard PCNL; delayed pseudoaneurysm or arteriovenous fistula presenting as haematuria 5–14 days post-operatively requires angioembolisation in 0.5–1%. Urosepsis from decompression of an infected collecting system is a major risk (2–5%) — mitigated by ensuring sterile pre-operative urine, appropriate prophylactic antibiotics (cephalosporin or aminoglycoside), and avoiding high-pressure irrigation in infected systems. Adjacent organ injury (colon, spleen, liver, pleura) occurs in 0.3–0.8%; colon injury requires diversion if not immediately recognised. Pleural injury causing haemothorax or pneumothorax from supracostal puncture above the 12th rib occurs in 2–5% of supracostal access cases — managed with chest drain. Residual stone fragments requiring further treatment (second-look flexible ureteroscopy or further PCNL) affect 10–15% of cases, particularly after staghorn stone treatment. Ureteric stricture from injury during access or stone manipulation occurs in 1–2% and may require endoscopic or surgical management.

The nephrostomy tube (if placed) is clamped on post-operative day 1 and removed when urine output via the ureter confirms no obstruction — typically day 1–2 for standard PCNL. The patient is discharged on day 2–3 with oral antibiotics (trimethoprim or nitrofurantoin for 5–7 days) and analgesia (paracetamol, ibuprofen). A ureteric stent (if placed) is removed cystoscopically at an outpatient appointment 1–2 weeks later. Haematuria (pink or blood-stained urine) is expected for 24–72 hours and resolves with hydration. High fluid intake (2–3 litres daily) is maintained throughout recovery. Light activities resume within 3–5 days; return to desk work at 1–2 weeks; manual work at 2–4 weeks. A follow-up CT urogram or plain X-ray at 4–6 weeks assesses stone-free status. Metabolic stone workup (24-hour urine collection for calcium, oxalate, citrate, uric acid, sodium, creatinine) and dietary counselling are recommended for all patients with recurrent stone disease to reduce the risk of further stone formation.